We are thrilled to announce that, through our Double Helix Venture Fund, we have invested in Baigene (www.baigene.com). 🚀
This investment is a natural step in a relationship that began some time ago. We had the privilege of supporting the founders in creating the Baigene Method, a globally pioneering methodology. Now, we are going further by joining the founding team and providing the capital needed to scale their business across Spain and, subsequently, worldwide.
Why Baigene? Because they are redefining the future of personalized health.
Baigene is the first company in the world with more than 2,000 clients who have improved their performance, health, and well-being through a deep understanding of their genetics. Their proprietary genetic test, unique in the market, is used by elite professional athletes as well as by people seeking healthier, more active aging.
Their approach is revolutionary. The Baigene Method, protected by the company, goes far beyond genetic analysis. It integrates these scientific insights with monthly tracking of metabolic expression to design fully personalized training and nutrition plans. The result is measurable and lasting improvements in clients’ health and performance. 🧬
We firmly believe Baigene is not just a company; it is the birth of a new category that unites sports genetics with preventive health. They are tackling a massive global opportunity, building from the Basque Country and Spain a company with the potential to become a worldwide reference.
At Double Helix, supporting companies like Baigene is part of our DNA. We are inspired by their vision, scientific rigor, and the real-world impact they are already creating. We are convinced this is just the beginning of an incredible journey.
We invite investors, institutions, and potential partners to connect with us. Double Helix will continue to make similar investments in our target sectors. Visit www.doublehelix.vc to learn more about our investments and join us. Together, we can take health to the next level.